Skip to main content
INKON Life Technology Co., Ltd. logo

INKON Life Technology Co., Ltd. — Investor Relations & Filings

Ticker · 300143 ISIN · CNE100000XF6 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,851 across all filing types
Latest filing 2021-07-23 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300143

About INKON Life Technology Co., Ltd.

https://www.inkonlife.com

INKON Life Technology Co., Ltd. specializes in the development and manufacture of advanced medical equipment and digital healthcare solutions. The company focuses on two primary sectors: radiotherapy equipment and digital medical services. Its core product portfolio includes high-precision radiotherapy systems, such as the Gamma Knife, and medical infusion systems. INKON Life leverages Internet of Things (IoT) technology to provide integrated digital hospital solutions, aiming to improve clinical efficiency and patient outcomes. The company serves oncology centers and medical institutions by providing comprehensive cancer treatment solutions and smart healthcare management platforms. By combining medical engineering with digital innovation, INKON Life focuses on the modernization of radiotherapy and the digital transformation of healthcare delivery.

Recent filings

Filing Released Lang Actions
重大资产购买暨关联交易报告书（草案）（二次修订稿）摘要
Audit Report / Information Classification · 95% confidence The document is titled as a "重大资产购买暨关联交易报告书（草案）（二次修订稿）摘要" which translates to "Major Asset Purchase and Related Party Transaction Report (Draft) (Second Revised Edition) Summary." It details a significant asset purchase transaction by 盈康生命科技股份有限公司, including transaction parties, asset valuation, financial impacts, approvals, and related legal and financial advisory opinions. The document includes detailed financial data, transaction structure, and compliance with regulatory requirements, indicating it is a comprehensive report on a major asset acquisition and related party transaction. It is not a simple announcement or a brief summary but a detailed report with substantive financial and transactional information. This fits the category of a detailed report on a major asset purchase and related party transaction, which aligns with the Audit Report / Information (AR) category, as it includes audit reports, evaluations, and detailed transaction disclosures but is not a full annual or quarterly report. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2020
2021-07-23 Chinese
关于重大资产购买暨关联交易报告书（草案）修订说明的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding revisions to a draft report on a major asset purchase and related party transaction by 盈康生命科技股份有限公司. It details updates and supplementary disclosures to the draft report, including approvals, risk disclosures, asset evaluations, and contract details. The document is relatively short (1631 characters) and serves as a notice about changes to a report draft rather than the report itself. It does not contain full financial statements or comprehensive financial data but rather updates on a transaction-related report. This fits best with the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including major asset purchases and related transactions.
2021-07-23 Chinese
第五届董事会第十次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the fifth board of directors' tenth (extraordinary) meeting of Yingkang Life Technology Co., Ltd. It includes voting results on a major asset restructuring and related party transaction, specifically the purchase of 100% equity of Suzhou Guangci Tumor Hospital from a related party. The document contains detailed terms of the transaction, payment schedules, performance commitments, breach liabilities, and conditions for effectiveness. It also mentions that these resolutions will be submitted to the shareholders' meeting for approval. The content is focused on board decisions and management-level approvals related to a significant transaction, not a full annual or interim financial report, nor a regulatory filing or announcement of a report. It is not a call transcript, earnings release, or proxy solicitation. The document is a formal board meeting resolution announcement with detailed management information about the transaction and related governance matters. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (6430 characters) and detailed content support this classification with high confidence.
2021-07-23 Chinese
关于本次重组方案调整不构成重大调整的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Yingkang Life Technology Co., Ltd. regarding adjustments to a major asset restructuring plan. It details changes in the payment terms of a share transfer agreement and explicitly states that these adjustments do not constitute a major change to the restructuring plan. The document includes board meeting approvals and independent director opinions. The content focuses on the restructuring transaction and related agreements rather than presenting full financial statements or detailed financial performance data. The document length is relatively short (1808 characters), and it serves as a formal announcement about the restructuring plan adjustment rather than the full restructuring report or financial report. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including restructuring announcements.
2021-07-23 Chinese
独立董事关于第五届董事会第十次（临时）会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on a specific board meeting regarding a major asset restructuring and related party transaction. It references compliance with Chinese securities regulations and company governance rules. The content focuses on the independent directors' approval and opinion on the restructuring plan and related agreements. It is not a full annual or interim report, nor an earnings release or call transcript. It is not a proxy solicitation or voting result announcement. The document is a formal opinion related to board matters and governance, specifically about a major asset restructuring transaction. This fits best under Regulatory Filings (RNS) as it is a regulatory disclosure related to corporate governance and transaction approval, but not a full audit report or management report. The document length is short and it is a formal opinion rather than a full report or presentation.
2021-07-23 Chinese
关于深圳证券交易所创业板非许可类重组问询函【2021】第9号回复的公告
Audit Report / Information Classification · 95% confidence The document is a detailed response to an inquiry letter from the Shenzhen Stock Exchange regarding a non-permitted restructuring involving a significant asset purchase and related party transaction. It includes extensive financial data, business performance analysis, valuation methods, and future earnings forecasts related to the acquisition of Suzhou Guangci hospital. The document discusses asset valuation, profitability, business metrics, and payment terms tied to performance commitments. It is a comprehensive disclosure related to a major asset acquisition and restructuring transaction, typical of filings made in connection with significant corporate reorganizations or major asset purchases. The presence of detailed financial analysis, valuation, and transaction terms indicates this is not a simple announcement but a substantive report. Given the context and content, this document fits best under the category of Audit Report / Information (AR), as it provides detailed audit-related information, valuation, and regulatory inquiry responses related to a restructuring transaction, but it is not a full annual report or earnings release. It is also not a merger proxy or tender offer filing, but a regulatory inquiry response with detailed financial and operational data supporting the transaction. H1 2021
2021-07-23 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.